Qiagen N.V. (NYSE:QGEN)

Qiagen N.V. QGEN

Healthcare - Medical - Diagnostics & Research - NYSE - NL

Watchlist

$ 41.27

-1.95 %

$ 9.16 B

Market Cap

91.71

P/E

1. INTRINSIC VALUE

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing.[ Read More ]

The intrinsic value of one QGEN stock under the base case scenario is HIDDEN Compared to the current market price of 41.3 USD, Qiagen N.V. is HIDDEN

QGEN Intrinsic Value
HIDDEN

SHOW

2. FUNDAMENTAL ANALYSIS

Price Chart QGEN

FINANCIALS

Annual
Quarterly

1.97 B REVENUE

Growth Rates

1Year -8.23%

3Years 1.66%

5Years 5.53%

7Years 5.65%

10Years 4.20%

445 M OPERATING INCOME

Growth Rates

1Year -16.22%

3Years -7.08%

5Years 10.80%

7Years 23.99%

10Years 21.53%

341 M NET INCOME

Growth Rates

1Year -19.35%

3Years 66.73%

5Years 12.38%

7Years 22.96%

10Years 17.32%

459 M OPERATING CASH FLOW

Growth Rates

1Year -35.76%

3Years -2.27%

5Years 5.03%

7Years 4.33%

10Years 5.90%

-87.7 M INVESTING CASH FLOW

Growth Rates

1Year 87.94%

3Years 42.17%

5Years 16.14%

7Years 9.70%

10Years 10.01%

-434 M FINANCING CASH FLOW

Growth Rates

1Year -244.85%

3Years -80.05%

5Years -17.12%

7Years -69.93%

10Years -20.23%

496 M REVENUE

Growth Rates

1Year -8.23%

3Years 1.66%

5Years 5.53%

7Years 5.65%

10Years 4.20%

-228 M OPERATING INCOME

Growth Rates

1Year -16.22%

3Years -7.08%

5Years 10.80%

7Years 23.99%

10Years 21.53%

-183 M NET INCOME

Growth Rates

1Year -19.35%

3Years 66.73%

5Years 12.38%

7Years 22.96%

10Years 17.32%

167 M OPERATING CASH FLOW

Growth Rates

1Year -35.76%

3Years -2.27%

5Years 5.03%

7Years 4.33%

10Years 5.90%

-17.8 M INVESTING CASH FLOW

Growth Rates

1Year 87.94%

3Years 42.17%

5Years 16.14%

7Years 9.70%

10Years 10.01%

-127 M FINANCING CASH FLOW

Growth Rates

1Year -244.85%

3Years -80.05%

5Years -17.12%

7Years -69.93%

10Years -20.23%

Balance Sheet Decomposition Qiagen N.V.

6.12 B ASSETS
2.31 B LIABILITIES

Current Assets	2.15 B
Cash & Short-Term Investments	1.06 B
Receivables	516 M
Other Current Assets	574 M
Non-Current Assets	3.97 B
Long-Term Investments	29.5 M
PP&E	870 M
Other Non-Current Assets	3.07 B

Current Liabilities	1.08 B
Accounts Payable	84.2 M
Short-Term Debt	610 M
Other Current Liabilities	385 M
Non-Current Liabilities	1.23 B
Long-Term Debt	1 B
Other Non-Current Liabilities	227 M

EFFICIENCY

Earnings Waterfall Qiagen N.V.

Revenue	1.97 B
Cost Of Revenue	742 M
Gross Profit	1.22 B
Operating Expenses	778 M
Operating Income	445 M
Other Expenses	104 M
Net Income	341 M

RATIOS

62.23% GROSS MARGIN

Averages

1Year 62.23%

3Years 63.77%

5Years 64.56%

7Years 64.94%

10Years 64.65%

22.66% OPERATING MARGIN

Averages

1Year 22.66%

3Years 25.15%

5Years 25.43%

7Years 22.25%

10Years 18.88%

17.37% NET MARGIN

Averages

1Year 17.37%

3Years 19.96%

5Years 12.22%

7Years 10.95%

10Years 10.12%

8.96% ROE

Averages

1Year 8.96%

3Years 12.58%

5Years 7.81%

7Years 6.84%

10Years 6.03%

5.58% ROA

Averages

1Year 5.58%

3Years 6.88%

5Years 4.22%

7Years 3.60%

10Years 3.27%

6.65% ROIC

Averages

1Year 6.65%

3Years 8.38%

5Years 7.07%

7Years 5.90%

10Years 5.39%

FREE CASH FLOW ANALYSIS

Free Cash Flow Analysis Qiagen N.V.

Net Income	341 M
Depreciation & Amortization	205 M
Capital Expenditures	-163 M
Stock-Based Compensation	47.1 M
Change in Working Capital	-187 M
Others	-22.7 M
Free Cash Flow	297 M

3. WALL STREET ANALYSTS ESTIMATES

Wall Street Analysts Price Targets Qiagen N.V.

Wall Street analysts predict an average 1-year price target for QGEN of $48.3 , with forecasts ranging from a low of $46 to a high of $50 .

QGEN Lowest Price Target Wall Street Target

46 USD 11.46%

QGEN Average Price Target Wall Street Target

48.3 USD 17.11%

QGEN Highest Price Target Wall Street Target

50 USD 21.15%

4. DIVIDEND ANALYSIS

0.00% DIVIDEND YIELD

1.32 USD DIVIDEND PER SHARE

5. COMPETITION

Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety.

5.2 USD

NEOG

Overvalued 64.41%

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research.

-0.069 USD

ACRS

Overvalued 103.37%

IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

148 USD

IQV

Overvalued 23.02%

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas.

404 USD

MEDP

Undervalued 30.03%

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally.

710 USD

ICLR

Undervalued 274.25%

Sotera Health Company provides sterilization, and lab testing and advisory services in the United States, Canada, Europe, and internationally. The company's sterilization services include gamma and electron beam irradiation, and EO processing; Nelson Labs comprise microbiological and analytical chemistry testing; and advisory services for medical device and biopharmaceutical industries.

-5.62 USD

SHC

Overvalued 139.27%

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

36.2 USD

NTRA

Overvalued 75.20%

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments.

-12.6 USD

NEO

Overvalued 183.95%

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients.

53 USD

Undervalued 82.18%

6. Ownership

Insider Ownership Qiagen N.V.

Summary
Transactions

Sold

0-3 MONTHS

0 USD 0

3-6 MONTHS

0 USD 0

6-9 MONTHS

0 USD 0

9-12 MONTHS

0 USD 0

Bought

0 USD 0

0-3 MONTHS

0 USD 0

3-6 MONTHS

0 USD 0

6-9 MONTHS

0 USD 0

9-12 MONTHS

Date	Value	Insider	Amount	Avg Price

7. News

QGEN Collaborates With McGill University Centre: Stock to Gain? QIAGEN joins forces with McGill University Centre for Microbiome Research to generate evidence-based knowledge for medicine and public health. zacks.com - 3 days ago

Don't Overlook Qiagen (QGEN) International Revenue Trends While Assessing the Stock Evaluate Qiagen's (QGEN) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance. zacks.com - 5 days ago

Why Qiagen (QGEN) is a Top Value Stock for the Long-Term Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. zacks.com - 1 week ago

Qiagen N.V. (QGEN) Q3 2024 Earnings Call Transcript Qiagen N.V. (NYSE:QGEN ) Q3 2024 Earnings Conference Call November 7, 2024 9:30 AM ET Company Participants John Gilardi - VP, Head of Corporate Communications and IR Thierry Bernard - CEO Roland Sackers - CFO Conference Call Participants Patrick Donnelly - Citi Odysseas Manesiotis - Berenberg Matt Sykes - Goldman Sachs Doug Schenkel - Wolfe Research Aisyah Noor - Morgan Stanley Michael Ryskin - Bank of America Casey Woodring - JP Morgan Andrew Brackmann - William Blair Operator Ladies and gentlemen, thank you for standing by. seekingalpha.com - 1 week ago

QIAGEN Stock Flat Post Q3 Earnings & Revenue Beat, 2024 EPS View Up QGEN delivers another solid performance in the third quarter of 2024, with both the top and bottom lines surpassing estimates. zacks.com - 1 week ago

Compared to Estimates, Qiagen (QGEN) Q3 Earnings: A Look at Key Metrics While the top- and bottom-line numbers for Qiagen (QGEN) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. zacks.com - 1 week ago

Qiagen (QGEN) Q3 Earnings and Revenues Top Estimates Qiagen (QGEN) came out with quarterly earnings of $0.57 per share, beating the Zacks Consensus Estimate of $0.54 per share. This compares to earnings of $0.52 per share a year ago. zacks.com - 1 week ago

Diagnostics firm Qiagen reports rise in third-quarter revenue Qiagen reported a rise in third-quarter revenue on Wednesday, owing to strong sales of its diagnostic devices. reuters.com - 1 week ago

QGEN Stock Set to Gain From FDA's Clearance of QIAstat-Dx Mini Panel QIAGEN wins FDA clearance for the QIAstat-Dx mini panel to improve precision in outpatient respiratory treatment. zacks.com - 1 week ago

Qiagen (QGEN) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates Beyond analysts' top -and-bottom-line estimates for Qiagen (QGEN), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2024. zacks.com - 1 week ago

QIAGEN receives FDA clearance of QIAstat-Dx meningitis/encephalitis panel to support emergency diagnostics QIAstat-Dx Meningitis/Encephalitis Panel cleared in the U.S. for use in clinical settings to help diagnose central nervous system infections // Fourth FDA clearance marks milestone in 2024 in successful expansion of QIAstat‑Dx tests developed specifically for the U.S. // QIAGEN now offers broad menu with FDA-cleared tests for respiratory, gastrointestinal and central nervous system infections – and plans for further expansion // QIAstat-Dx delivers results in about one hour with real-time PCR, ensuring fast and accurate results to support clinical decision-making QIAstat-Dx Meningitis/Encephalitis Panel cleared in the U.S. for use in clinical settings to help diagnose central nervous system infections // Fourth FDA clearance marks milestone in 2024 in successful expansion of QIAstat‑Dx tests developed specifically for the U.S. // QIAGEN now offers broad menu with FDA-cleared tests for respiratory, gastrointestinal and central nervous system infections – and plans for further expansion // QIAstat-Dx delivers results in about one hour with real-time PCR, ensuring fast and accurate results to support clinical decision-making globenewswire.com - 1 week ago

QIAGEN receives FDA clearance for QIAstat-Dx mini panel to improve precision in outpatient respiratory treatment QIAstat-Dx Respiratory Panel Mini targets the five most actionable respiratory pathogens in outpatient settings to help clinicians make precise treatment decisions // With the new test and the 21-target QIAstat-Dx Respiratory Panel Plus, clinicians can fine-tune their diagnostic approach for individual patients, promoting better diagnostic stewardship // FDA decision marks third positive U.S. regulatory outcome for QIAstat-Dx to date in 2024 QIAstat-Dx Respiratory Panel Mini targets the five most actionable respiratory pathogens in outpatient settings to help clinicians make precise treatment decisions // With the new test and the 21-target QIAstat-Dx Respiratory Panel Plus, clinicians can fine-tune their diagnostic approach for individual patients, promoting better diagnostic stewardship // FDA decision marks third positive U.S. regulatory outcome for QIAstat-Dx to date in 2024 globenewswire.com - 2 weeks ago

8. Profile Summary

Qiagen N.V. QGEN

COUNTRY NL

INDUSTRY Medical - Diagnostics & Research

MARKET CAP $ 9.16 B

Dividend Yield 0.00%

Description QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.

Contact Hulsterweg 82, Venlo, 5912 PL https://www.qiagen.com

IPO Date June 28, 1996

Employees 5800

Officers Dr. Roland Sackers Chief Financial Officer, MD & Member of Management Board Mr. Jean-Pascal Viola Senior Vice President & Head of Corporate Strategy and Business Development Dr. Jonathan G. Sheldon Ph.D. Senior Vice President & Head of the QIAGEN Digital Insights Business Area Mr. Fernando Beils Senior Vice President & Head of the Molecular Diagnostics Business Area Ms. Stephany Foster Senior Vice President & Head of Human Resources Mr. Thierry Bernard Chief Executive Officer, MD & Member of Management Board Dr. Thomas Theuringer Senior Director & Head of External Communications Mr. John Gilardi Vice President of Corporate Communications & Investor Relations Dr. Thomas Schweins Senior Vice President of Life Science Business Area Mr. Antonio Santos Senior Vice President & Head of Global Operations

Price Chart QGEN

Qiagen N.V. QGEN

Premium Plan

Unlimited Plan